Ustekinumab for the Treatment of Giant Cell Arteritis

NCT02955147 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

13

Enrollment

OTHER

Sponsor class

Stopped Inefficacy

Conditions

Giant Cell Arteritis
Temporal Arteritis
Horton's Disease

Interventions

DRUG: Ustekinumab
DRUG: Prednisone

Sponsor

Massachusetts General Hospital